Formation: 1958
Medical history: originally named Shanghai Institute of Thoracic Disease, the first director Huang Jiaqi. 1963 renamed Shanghai Institute of Cardiovascular Disease, Shen Kefei, director. 1973 to restore the institute, Shi Meixin, director. The current director Royston Chen, honorary director Meixin Shi, deputy director Junbo Ge, Qiang Zhao, and Xianhong Shu. The Institute has 107 employees, including 10 full professors and 30 associate professors. There are 6 doctoral supervisors and 7 master's supervisors. The institute has clinical and experimental departments such as cardiology (Ward 19, Ward 23, Ward 30, CCU), cardiac surgery (Ward 31, Ward 32, ICU), cardiac catheterization, cardiac ultrasound diagnostic laboratory, electrocardiography, key laboratory of viral heart disease of the ministry of health, central laboratory, cardiovascular epidemiology and statistics, etc., and owns the 10-story cardiovascular building with a floor area of 8442M2, total number of beds 220, laboratories, and a total number of beds 220, and a total number of beds 220. The number of beds is 220, and the laboratory area is about 1200 M2. There are more than 30 pieces of advanced scientific research instruments and equipments, such as ultra-low-temperature refrigerator, fluorescence microscope, floor-standing high-speed centrifuge, desktop high-speed freezing centrifuge, quantitative PCR instrument, three-dimensional reconstruction instrument, ultrasonic ablator, vertical electrophoresis, high-pressure electrophoresis, spectrophotometer, etc. The Institute has been designated by the World Health Organization (WHO) for cardiovascular disease research and study since 1980, and has been awarded the "World Health Organization (WHO)" award for the "World Health Organization (WHO)" award. Since 1980, the institute has been designated by the World Health Organization as a cooperative center for cardiovascular disease research and training, and was approved as the Shanghai Clinical Medical Center for Cardiovascular Disease in 2002. The Department of Cardiology has been listed as a key discipline of higher education institutions in China. The Laboratory of Viral Heart Disease is a key laboratory of the Ministry of Health.
Main research areas: research on epidemiology and prevention of cardiovascular diseases, 1. research on pathogenesis, diagnosis and treatment of coronary heart disease, including epidemiology, biochemical research on experimental atherosclerotic blood lipids, diagnostic X-ray imaging as well as diagnostic ultrasonography, interventional treatment of coronary heart disease, intravascular ultrasonography diagnosis of coronary heart disease, and surgical treatment of coronary heart disease and its complications; 2. research on pathogenesis of viral heart disease at molecular level. Research on the pathogenesis, diagnosis and treatment of viral heart disease at the molecular level, including epidemiology, virology, immunological diagnosis, and combined traditional Chinese and western medicine; 3. Basic and clinical research on heart failure; 4. Research on cardiac ultrasound, including the application of esophageal ultrasound examination technology, vascular luminal ultrasound, multiplanar trans-esophageal three-dimensional reconstruction ultrasound imaging, and ultrasound ablation of coronary artery atherosclerosis; 5. Research on electrophysiological diagnosis and treatment of cardiac arrhythmia, and research and clinical application of artificial heart pacing technology; 6. Surgical treatment of heart valve disease, treatment of various congenital heart diseases, research on new artificial heart valves and research on assisted circulation. Carrying out surgery of coronary artery bypass grafting, heart transplantation (surgical treatment of end-stage heart disease) and artificial aortic valve transplantation.
He has completed more than 50 projects at the municipal level, such as the National 7th Five-Year Plan, the 8th Five-Year Plan, the key projects of the Ministry of Health, and the leading specialties of medicine in Shanghai. At present, it is undertaking more than 20 projects such as 973 "863" National Key Basic Research, Tenth Five-Year Plan, "211 Project", Shanghai Clinical Medical Center for Cardiovascular Diseases, Key Projects of Shanghai Medical Development Fund, and National Natural Science Foundation of China, etc. The research funding reaches 12 million yuan. The research fund reaches 12 million RMB. In the past five years, he has won 14 scientific and technological progress awards at the municipal level and above, published nine monographs and more than 450 papers, and was awarded a patent.
Has trained 4 postdoctoral fellows, 77 PhDs, 77 masters, 4 postdoctoral fellows, 22 doctoral students and 32 masters in school.
The Institute of Cardiology is entrusted by the Ministry of Health to organize the national study class of cardiology every year, which has been 26 sessions so far.
Cardiology
Zhongshan Hospital of Fudan University
Cardiology, as a sub-discipline of internal medicine, was founded in 1958, and its founder was Prof. Tao Shouqi, a famous cardiovascular specialist in China, who was also the first director of the Department of Cardiology, and it was named as a key discipline of the whole country in 1989, and a leading discipline of Shanghai Municipal Bureau of Health in 1994, and was listed in the "211 Project" of Shanghai Municipal Bureau of Health in 1997. In 1994, it was named the leading discipline of Shanghai Municipal Health Bureau, and in 1997, it was included in the key disciplines of the "211 Project" development plan, and in 2002, it was identified as the Shanghai Cardiovascular Clinical Medical Center, and was designated as the clinical pharmacology base in China.
The overall medical level of the Department of Cardiology is leading in East China and among the best in China. Since the 1950s, it has successively been the first or earlier in China to perform right and left heart catheterization, electrophysiological examination of cardiac arrhythmia, extracorporeal electric defibrillation and repetition, coronary angiography, permanent pacemaker, extracorporeal counterpulsation for coronary artery disease, ablation of ventricular tachycardia by transcatheter catheterization, placement of automated pacing and repetitive defibrillator via vein, intracoronary laser thrombolysis, and intracoronary ultrasound, among others.
Cardiac Surgery Department
The Department of Cardiac Surgery was established in 1947 and is headed by Prof. Huang Jia-tei, who has accomplished many domestic "firsts" in the course of decades of development. The Department of Cardiothoracic Surgery was the first in China to study the artificial static pendant screen heart-lung machine and carry out deep cryogenic extracorporeal circulation for direct vision surgery, such as VSD, ASD and F4 corrective surgery for congenital heart disease, mitral valve closure insufficiency repair and cryogenic ventricular septal defect suture, etc. The Department of Cardiothoracic Surgery set up the "Shanghai Valve Center" to carry out the research of domestic valves in 1978, using homogeneous dura mater, porcine dura mater and piggy bank. With the same kind of dura mater, porcine aortic valve and bovine pericardium made of biological valves successfully, and the application of biological valves to perform mitral, aortic valve, tricuspid valve replacement, the types of surgery from the development of a single valve to double valves, three valves replacement surgery. We also perform aortic aneurysm, ascending aortic valve replacement, coronary artery bypass grafting, transposition of large vessels, limited hypertrophic cardiomyopathy (IHSS) and complex heart surgery. A wide range of cardiac surgeries have been performed, including: congenital heart disease, heart valve disease, coronary artery disease, large artery aneurysm, cardiac tumors, Marfan's syndrome and end-stage cardiomyopathy. Heart transplantation, surgical treatment of aortic coarctation/aneurysm, minimally invasive cardiovascular surgery, valvular repair and plasty, and surgical treatment of complex coronary heart disease are its specialties. The annual operation volume reaches more than 2,500, and the success rate of the operation reaches up to 98%, which puts the treatment level in a leading position in China. The successful in-situ heart transplantation for end-stage heart disease led by Prof. Wang Chunsheng won the second prize of China Medical Science and Technology Award and the second prize of Shanghai Science and Technology Award. The recent applications of minimally invasive cardiovascular surgery include: minimally invasive mitral valve repair/replacement, minimally invasive aortic valve replacement, minimally invasive atrial defect repair, robotic-assisted minimally invasive coronary artery bypass grafting, and minimally invasive labyrinthine surgery for the treatment of atrial fibrillation, which is one of the leading operations in China and has excellent therapeutic effects.
Completed and undertook many scientific research projects, and won many scientific and technological achievement awards from the Ministry of Health and Shanghai Municipality. She has lectured and demonstrated the relevant chapters of Cardiac Surgery at Fudan University, and served as a lecturer for the Chinese Cardiothoracic Surgery Study Class and a lecturer for the postgraduate class. She invites foreign experts to the hospital for lectures and surgeries, and participates in the activities of foreign guests' symposiums in foreign hospitals for academic exchanges and knowledge updating. Formation time: 1968
Brief medical history: the predecessor of Fudan University Liver Cancer Research Institute was the tumor group of Zhongshan Hospital of Shanghai First Medical College established in 1968, and the liver tumor group of Zhongshan Hospital was formally set up in 1969 with wards. 1978 was renamed as the Liver Cancer Research Laboratory of Zhongshan Hospital, which was divided into wards and laboratories at the beginning. After that, it developed and expanded continuously, and was renamed as Liver Cancer Research Institute of Shanghai Medical University (SMMU) in 1988, which was subordinate to SMMU, and renamed as Liver Cancer Research Institute of Shanghai Medical University (LCRI) after the merger of the two universities in 2000. It is one of the two major research centers for liver cancer prevention and treatment in China, and is one of the national key disciplines (Oncology), Shanghai Clinical Medical Center of Liver Tumor, Shanghai Leading Medical Specialty (Liver Oncology), as well as one of the key disciplines (Oncology) of the "211 Project" of Shanghai Medical University, and one of the key disciplines (Oncology) of the "985 Project" of Shanghai Medical University. It is also the key discipline of Shanghai Medical University's "Project 211" construction project (Oncology) and Shanghai Medical University's "Project 985" top priority discipline.
Clinical specialties are early diagnosis and early treatment of liver cancer, and resection after reduction of unresectable liver cancer. It has also developed special programs such as surgical resection for postoperative recurrence of liver cancer, cryotherapy, microwave, ultrasound intervention, and biotherapy. Since 1995, we have started the clinical comprehensive treatment research focusing on the prevention and treatment of postoperative recurrence and metastasis of hepatocellular carcinoma, exploring the comprehensive prevention and treatment program of postoperative recurrence of hepatocellular carcinoma, further prolonging the survival period of patients with hepatocellular carcinoma and improving the prognosis. The Institute has accumulated nearly 4,000 cases of liver cancer diagnosis and treatment experience, and was the first to carry out diagnosis and treatment of small liver cancer, re-resection after recurrence, and resection after shrinkage of unresectable liver cancer, with a 5-year survival rate of 60-70%, and so far there are 368 cases of liver cancer patients who have survived for more than 5 years, 112 cases who have survived for more than 10 years, and one case who has survived for the longest period of time, which is 38 years, and it is at the leading position in the international community.
The laboratories of the institute include sterile animal model laboratory, cell biology laboratory, immunology laboratory, pathology laboratory, isotope laboratory, molecular biology and gene therapy laboratory. It has large-scale equipments such as ultracentrifuge, capillary electrophoresis, DNA synthesizer, peptide synthesizer, liquid flash detector and high performance liquid chromatograph. The laboratory has successively undertaken the research of major projects from the Sixth Five-Year Plan to the Ninth Five-Year Plan, such as the National Science and Technology Tackling Project, the Chinese Medical Foundation of the United States, and the Key Discipline Fund of the Ministry of Health, etc. The laboratory has been awarded the First Class National Scientific and Technological Progress Award. He has been awarded the first and third prizes of National Scientific and Technological Progress, the first prize of Shanghai Scientific and Technological Progress, and many prizes of Scientific and Technological Progress of the Ministry of Health, as well as the Gold Medal of the American Institute of Cancer Research. He is now responsible for one sub-topic of the malignant tumor project of the National Key Basic Research Development Program (973), two sub-topics of the National Tenth Five-Year Plan, two sub-topics of the major project of Shanghai Leading Medical Specialties, two sub-topics of the major project of the Shanghai Medical Development Fund, as well as projects of the National Natural Science Foundation of China, and the Foundation of the Ministry of Health, and has participated in the "863 High-Tech Program". He has also participated in the research of major projects such as "863 High-Tech Program".
The Institute is a doctoral degree and master's degree granting center of Fudan University, with a postdoctoral station (Clinical Medicine), and has 7 doctoral supervisors, 5 master's supervisors, 3 postdoctoral supervisors, 42 doctoral supervisors, 38 master's supervisors, and 1 postdoctoral supervisor. 31 doctoral supervisors and 15 master's supervisors are currently enrolled in the Institute. Commissioned by the Ministry of Health, she hosts the National Continuing Medical Education Program - National Liver Cancer Diagnosis and Treatment Progress Workshop every year.
He has edited the English version of Subclinical Hepatocellular Carcinoma and Primary Liver Cancer published by Springer, and edited the Chinese version of Primary Liver Cancer (1st and 2nd editions) as well as Modern Oncology (awarded the Third Prize of the book category of National Scientific and Technological Progress). Scientific and Technological Progress (Third Prize in the Book Category). He has been invited to write articles in more than ten internationally renowned monographs. He has led the organization of four large-scale Shanghai International Hepatitis Conference on Liver Cancer and several national liver cancer conferences. Prof. Tang was a member of the International Union Against Cancer (1990-1998), the chairman of the 15th and 16th International Cancer Conferences on Liver Cancer, and has attended hundreds of international conferences as an invited speaker.In 1987, Prof. Tang was one of the 14 young and middle-aged scientists in China who were received by Deng Xiaoping and other leaders of the Party and the State.
Status of the department: The Institute of Liver Cancer consists of the Department of Liver Tumor Surgery, the Department of Internal Medicine and the Laboratory. It has nearly 100 specialized beds and well-equipped laboratories with an area of 900 square meters. With surgical treatment as the mainstay, comprehensive treatment research combining internal surgery, Chinese and western medicine, basic and clinical is the specialty of the institute. There are more than 40 medical and technical personnel, including 10 professors and 12 associate professors (associate chief physicians). The current director: Prof. Tang Zhaoyou, a renowned expert in liver cancer surgery and academician of the Chinese Academy of Engineering.
Department of Hepato-Oncology
The Department of Hepato-Oncology was established in 1968 as the Tumor Group of Sun Yat-sen Hospital, and the Liver Tumor Group of Sun Yat-sen Hospital, which is a combination of medical and surgical departments, was formally set up with wards in 1969, and the Department of Liver Cancer was officially set up with the approval of the Ministry of Health in 1978, and the Liver Cancer Laboratory was expanded to become the Institute of Liver Cancer Research of Shanghai Medical University in October, 1988. The Department of Hepato-Oncology is a clinical department that focuses on primary liver cancer and is closely integrated with the Department of Medicine and Surgery. The Department of Liver Cancer Surgery performs nearly 1,000 liver surgeries every year, with a resection rate of 60-80%, a five-year survival rate of 40-50%, and an operative mortality rate of 1-3%, which are all at the leading level in China. In China, we were the first to carry out early diagnosis and early treatment of small liver cancer, resection after recurrence of liver cancer, and resection after shrinkage of unresectable liver cancer, and the five-year survival rate after resection of small liver cancer reaches 60-70%. In particular, he has special features in the resection of huge liver tumors and the surgical diagnosis and treatment of hepatocellular carcinoma in the hepatoportal region. Liver transplantation has achieved good results in the treatment of end-stage cirrhosis, inborn metabolic disorders of the liver and cholestatic diseases. In the early years, the Department of Hepatic Oncology conducted screening and hepatic arteriography to improve the detection rate of small liver cancers. Subsequently, chemotherapy, immunotherapy, traditional Chinese medicine and other comprehensive treatments were developed. The focus of the Department of Hepatic Oncology is on the non-surgical treatment of liver tumors and the prevention and treatment of recurrence and metastasis after surgery, and it carries out radiological intervention (hepatic artery chemoembolization), ultrasound-guided local treatment (intra-local injections, portal vein chemotherapy, radiofrequency destruction therapy, etc.), chemotherapeutic drug treatment, and biological therapy.
General Surgery
The founder of the department is Prof. Shen Kefei, a famous surgeon. For more than half a century, through the efforts of several generations, the department has been at the leading level in China in many fields of medical teaching and scientific research, and has produced such famous surgeons at home and abroad as Huang Jiaqi, Cui Zhiyi, Feng Youxian, Wu Zhaoguang, Meng Chengwei, Wang Chenggall, Wu Zhaohan, etc. The Department of General Surgery has carried out many important and significant medical researches in China. The Department of General Surgery has carried out many major surgeries in China. Such as pancreaticoduodenectomy, regular hepatic lobectomy, artificial blood vessel transplantation, mesenteric inferior vena cava anastomosis. Main medical treatments: cholecystitis, cholelithiasis; appendicitis; benign thyroid tumors; colorectal and rectal cancer; gastric cancer; pancreatitis; pancreatic cancer; cholangitis; gallbladder and bile duct cancer; portal hypertension; thyroid cancer; metastatic cancer. The main surgical procedures carried out include: cholecystectomy; appendectomy; thyroidectomy; breast lumpectomy; caesarean section; inguinal hernia repair with high ligation; radical gastrectomy; radical mastectomy; right hemicolectomy; gastroduodenal perforation repair; DIXON surgery; MILE' surgery; subtotal thyroidectomy; left hemicolectomy; total thyroidectomy; modified breast cancer radical resection; and modified breast cancer radical resection; DIXON surgery; MILE' surgery; subtotal thyroidectomy; left hemicolectomy; total thyroidectomy; and modified breast cancer radical resection. resection; modified radical mastectomy; WHIPPLE' procedure; partial hepatectomy; total gastrectomy; extended radical mastectomy; total colectomy.
Main research interests are: surgical intensive care and surgical nutrition, comprehensive treatment of biliary pancreatic diseases, gastrointestinal surgery research, gastrointestinal dynamics research, endoscopic surgery. He has edited and co-edited more than 10 textbooks and monographs, undertaken more than 20 scientific research projects of the National Natural Science Foundation of China, ministries and municipalities, and won the first prize of Shanghai Scientific and Technological Progress and many other scientific and technological achievements. Establishment: 1936
Brief medical history: The Department of Orthopedics was established at the beginning of Sun Yat-sen Hospital in 1936, with Li Hongru as the director, and lasted for nearly twenty years. Clinically, the department was mainly focused on trauma orthopedics. The Department of Orthopaedic Surgery began its attempts at internal fixation of fractures in the late 1940s, and was the first to perform intervertebral discography in China in 1953. 1962 saw the launch of experimental research into small vessel surgical techniques, the study of a complete set of small vessels including microsurgical instruments, and a summary of experience comparing the basic techniques of various different sutures, different suture materials and small vessel grafts, etc. 1963 saw the success of the upper arm severance and reimplantation surgery. 1966 saw the success of the upper arm severance and reimplantation surgery. In 1963, he successfully performed the reconstruction of upper arm, and in 1966, in collaboration with Huashan Hospital, he successfully performed 5 cases of second toe one-stage transplantation for thumb reconstruction, and in 1970, he completed the first case of metal all-humerus replacement in Shanghai. In the same year, he succeeded in designing the Shanghai Type II artificial femoral head, which was firstly promoted in Shanghai, eliminating the original Type I artificial femoral head. 1974, he was the first to accept the newly emerging concept of limb preservation, and succeeded in limb reconstruction. 1976, he was the first to perform emergency anastomotic vascularized free flap transplantation surgery. In 1976, he was the first to perform free flap transplantation for acute anastomotic vessels, and in the same year, he started to perform knee arthroscopy, which contributed to the early development of arthroscopic surgery in Shanghai. 1980, he performed synovectomy or artificial joint replacement for rheumatoid arthritis, which was honored with the Scientific and Technological Achievement Award of the Ministry of Health. 1982, academician Chen Zhongwei, who was known as the "father of microsurgery in the world", was transferred to Zhongshan Hospital as the director of the Department of Orthopaedics, and established the department of orthopaedics. In 1982, Academician Chen Zhongwei, known as "the father of microsurgery in the world", transferred to Sun Yat-sen Hospital as the director of Department of Orthopedic Surgery, set up the Microsurgery Center Laboratory, and organized national microsurgery classes and seminars every year. He designed the iliopsoas transfer with spinning iliac deep vessel tip for the treatment of aseptic necrosis of femoral head in children and adults, and was the first to popularize the concept of AO and AO technique in Shanghai in 1988. He mainly treats spine, joints, trauma, bone and soft tissue tumors, bone and joint tuberculosis, osteomyelitis, peripheral nerve injury, hand diseases, and congenital deformities of bones and joints, etc. He is especially famous for his specialties in trauma internal fixation techniques, bone tumors, peripheral nerve injuries, arthroscopy and intervertebral discoscopy, lateral anterior decompression of thoracic and lumbar segments, ischemic necrosis of the femoral head, and chronic osteomyelitis. In recent years, she has developed new technologies such as "autologous bone marrow stem cell transplantation for the treatment of femoral head necrosis" and "T-saw vertebroplasty".
There are Bone and Joint Tumor Treatment Center, Arthroscopy Center and Tissue Engineering Center Laboratory. In 2002, the department received two grants from the National Natural Science Foundation of China for tissue engineering research, and also undertook the sub-projects of "973", a number of scientific research projects of the Ministry of Health and key projects of the Shanghai Municipal Science and Technology Commission, and was awarded a number of scientific and technological achievements of the Ministry of Health and the Shanghai Municipal Government.
Department status: 64 authorized beds, **** 34 physicians, including 5 professors and 10 associate professors. There are 2 doctoral supervisors and 5 master's supervisors. The annual surgical volume reaches more than 1500 units, and the number of annual outpatient visits is more than 50000.